The stock of Sangamo Therapeutics Inc. (NASDAQ:SGMO) increased by $0.06 on Monday to finish at $0.83, up 8.30 percent. The last five days have seen an average of 1,538,540 shares of common stock traded. 6 times new highs were reached in the current year, with a fall of -$2.3060. The average number of shares traded over the last 20 days was 1,356,365, while the average volume over the last 50 days totaled 2,018,174.
SGMO stock dropped -36.82% since last month. On 08/25/23, the company’s shares reached a one-month low of $0.7700. The stock touched a high of $5.88 on 01/13/23, after rallying from a low of $0.77 in 52 weeks. The price of SGMO stock has declined by -73.44% or -$2.3060 this year, reaching a new high 6 times. Still, the stock price is down -85.82% from the 52-week high.
Insider Transactions
SGMO stock investors should be aware that Sangamo Therapeutics Inc. (SGMO) stock had its last reported insider trading activity 364 days ago on Aug 30. On Aug 30, 10% Owner BIOGEN INC. sold 100,000 shares at $5.27 each. This transaction resulted in the insider making $526,520.
Valuation Metrics
Beta for the stock is 1.17. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 0.77, the price-to-book (PB) ratio of 0.62.
Financial Health
For the recent quarter, Sangamo Therapeutics Inc.’s quick ratio was 3.00, while its current ratio was 3.00, indicating its ability to pay off its debt. Sangamo Therapeutics Inc.’s EBITDA margin for the recent year was -169.97%, whereas its operating margin stood at -98.80% for the same period. Based on annual data, it had gross profit of $312.58 million and revenue of $111.3 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. SGMO’s return on assets (ROA) during the last 12 months has been -41.30%. There was a -68.40% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -67.70%.
Earnings Surprise
A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $6.84 million, while revenues fell by -329.53% to $157.96 million. EBITDA was -$66.86 million for the quarter. At the end of Sangamo Therapeutics Inc.’s most recent quarter, its liabilities totaled 91.43 million, while its total debt was $36.37 million. Equity owned by shareholders amounts to $177.11 million.
Technical Picture
Here’s a quick look at Sangamo Therapeutics Inc.’s (SGMO) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 27.51%, suggesting the stock is oversold, with a 88.24% historical volatility rate.
The stochastic %K and %D were 7.11% and 5.61% respectively, while the average true range (ATR) was 0.0893. Based on the 14-day stochastic reading of 18.29%, the RSI (14) reading is 29.36%. On the 9-day MACD Oscillator, the stock is at -0.0592, and the 14-day reading is at -0.1166.
Analyst Ratings
Sangamo Therapeutics Inc. (NASDAQ: SGMO) was downgraded by BofA Securities to a an Underperform rating in its latest research report. The stock was previously rated as a a Neutral. Analysts have assigned Sangamo Therapeutics Inc. (SGMO) an Overweight rating. SGMO is a stock that is recommended for selling by 0 brokerage firms, while 2 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 1 rate it overweight and 7 others recommend it as a buy.
What is SGMO’s price target for the next 12 months?
The current consensus forecast for the stock is between $1.50 and $10.00, with a median target price of $6.00. In analyzing these forecasts, the average price target given by analysts for Sangamo Therapeutics Inc. (SGMO) is $6.01.
